MS Clinical Trials in North Carolina
23 active trials · 12 recruiting
23 active multiple sclerosis clinical trials have at least one study site in North Carolina, 12 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 11 MS treatment centers in North Carolina; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in North Carolina
Recruiting
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Sponsor: TG Therapeutics, Inc.
No intervention
1 state728 participantsDetails ›
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Sponsor: TG Therapeutics, Inc.
Ublituximab · Placebo
25 states800 participantsDetails ›
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Sponsor: Amgen
Ocrelizumab (US) · Ocrelizumab (EU)
17 states444 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Sponsor: Novartis Pharmaceuticals
Remibrutinib oral treatment · Ocrelizumab
18 states360 participantsDetails ›
RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Frexalimab
6 states160 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsor: TG Therapeutics, Inc.
No Intervention
29 states500 participantsDetails ›
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Sponsor: TG Therapeutics, Inc.
No intervention
4 states16 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
Recruiting
Retinal Imaging in Neurodegenerative Disease
Sponsor: Duke University
Retinal and Choroidal Imaging
1 state2000 participantsDetails ›
RecruitingPhase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)
15 states156 participantsDetails ›
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Sponsor: Biogen
Diroximel Fumarate · Avonex
2 states908 participantsDetails ›
By invitation onlyNA
Effects of Stimulation Patterns of Deep Brain Stimulation
Sponsor: Duke University
Therapeutic Stimulation Patterns · Symptogenic Stimulation Patterns
3 states180 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
23 states1011 participantsDetails ›
Closed to new patientsPhase 4
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Disease modifying treatment (DMT)
19 states136 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
27 states1001 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
26 states1300 participantsDetails ›
Closed to new patientsPhase 2
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Sponsor: Sanofi
SAR441344 IV · placebo IV
4 states129 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Sponsor: Biogen
BIIB017 (peginterferon beta-1a) · Interferon beta type 1a
3 states152 participantsDetails ›
MS trials in other states
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.